If and when PRAN goes to Phase III trials, what will they cost? Depends on the size, construction, length and location. Based on the mixed results of Phase II, they will need large trials with identifiable sub-groups to help get an approval from the FDA. At least $50 million, probably double that if they do them right -- and I am talking about a 1,200-2,500 person trial. Currerntly, Medivation (MDVN) is doinga 525 person Phase III trial for their AD drug and I think they are taking a risk. They believe it is large enough given what they call the strength in their Phase II data -- I would like to see them do a larger trial. Neurochem (NRMX) did a thousand person trial but they messed up the data presentation and subgroup data and did not have proper controls separating out patients using other meds. Elan (ELAN) and Wyeth (WYE) are doing trials with more than 4,000 patients and using a new primary endpoint that is an amalgam of tests and metrics nver bfore used with the FDA. Stay tuned.